ArticleScientific data2025
A Multi-Omics Dataset of Prostate Cancer Response to Oncolytic Virus OH2 Treatment.
Article in Scientific data, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Oncolytic virus OHSV2 induces pyroptosis in bladder cancer cells via the TLR4/NLRP3/Caspase-1/GSDMD pathway.Molecular biomedicine · 2026Article
- Characteristics and therapeutic resistance mechanisms of the prostate cancer immune microenvironment: a comprehensive analysis from bench to clinic.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is the most common malignant tumor of the male genitourinary system, especially metastatic castration resistant prostate cancer (mCRPC), which currently lacks effective treatment methods. Immunotherapy has limited efficacy in prostate cancer, partly due to its immunosuppressive "cold" tumor microenvironment (TME). Oncolytic virus therapy, such as OH2 modified based on herpes simplex virus type 2, provides a new strategy for reshaping TME and enhancing immune activation. However, the complex regulatory mechanism of oncolytic viruses on TME has not been fully elucidated. This study used multi omics integrated analysis (transcriptomics, metabolomics, and single-cell RNA sequencing) to investigate the effect of OH2 intervention on prostate cancer TME. We systematically analyzed the gene expression changes, metabolic reprogramming, and immune cell dynamics after OH2 treatment using in vitro cell models and RM-1 mouse subcutaneous transplant tumor models. The dataset includes gene expression profiles, metabolic profiles, and single-cell transcriptomes, providing a resource for investigating OH2-induced changes in the prostate cancer TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.